Biederman, Joseph http://orcid.org/0000-0001-8233-663X
Fried, Ronna
DiSalvo, Maura
Woodworth, K. Yvonne
Biederman, Itai
Driscoll, Haley
Noyes, Elizabeth
Faraone, Stephen V.
Perlis, Roy H.
Funding for this research was provided by:
MGH Pediatric Psychopharmacology Council Fund
Article History
Received: 28 August 2019
Accepted: 1 June 2020
First Online: 26 June 2020
Compliance with ethical standards
: This study was approved by the Institutional Review Board at Massachusetts General Hospital.
: Dr. Biederman’s program has received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. Through MGH corporate licensing, he has a US patent (#14/027,676) for a non-stimulant treatment for ADHD, and a patent pending (#61/233,686) on a method to prevent stimulant abuse.Dr. Biederman reports grants from AACAP, grants from Feinstein Institute for Medical Research, grants from Food & Drug Administration, grants from Headspace, Inc., grants from Lundbeck AS, grants from Neurocentria, Inc., grants from NIDA, grants from Pfizer Pharmaceuticals, grants from Roche TCRC, Inc., grants from Shire Pharmaceuticals, Inc., grants from Sunovion Pharmaceuticals, Inc., grants from NIH, other from Avekshan LLC, personal fees from Akili, personal fees from Shire, personal fees from Alcobra, personal fees from Arbor Pharmaceuticals, Inc., grants from Department of Defense, grants from PamLab, personal fees from Aevi Genomics, personal fees from Guidepoint, personal fees from Medgenics, grants from Merck, grants from SPRITES, personal fees from Ironshore, personal fees from Piper Jaffray, personal fees from MGH Psychiatry Academy, and personal fees from APSARD, outside the submitted work; and Dr. Biederman’s program has received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance; these royalties were paid to the Department of Psychiatry at MGH. Through MGH corporate licensing, he has a US patent (#14/027,676) for a non-stimulant treatment for ADHD, and a patent pending (#61/233,686) on a method to prevent stimulant abuse.Dr. Ronna Fried received grant research support from Shire Pharmaceuticals and Roche Pharmaceuticals in the past 36 months.Maura DiSalvo, K. Yvonne Woodworth, Itai Biederman, Haley Driscoll, and Elizabeth Noyes have no conflicts to disclose.In the past 3 years, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Tris, Otsuka, Arbor, Ironshore, Shire, Akili Interactive Labs, VAYA, Ironshore, Sunovion, Supernus, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD.Dr. Perlis reports personal fees from Psy Therapeutics, personal fees from Genomind, and personal fees from RID Ventures, outside the submitted work.